Brief Summary:
The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination with pembrolizumab in patients with selected solid tumors.
Selected types of solid tumor that are pathologically confirmed unresectable advanced, recurrent, or metastatic.
Patients with at least 1 evaluable lesion assessed by Investigators within 28 days prior to the first dose of study treatment as defined per RECIST v1.1.
Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1 at Screening.
Life expectancy ≥ 3 months.
Has disease that is suitable for local treatment administered with curative intent.
Has a diagnosed and/or treated additional malignancy within 5 years prior to the first dose of study treatment except for: curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, and curatively resected in situ breast, cervical cancer, and prostate cancer.
Histologically/cytologically confirmed nasopharynx cancer. Has non-squamous histology NSCLC. If small cell elements are present, the patient is ineligible.
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
7
Treatment groupsSee each treatment group below.